RepliCel Life Sciences, Inc.: RepliCel Announces Appointment of Leading Dermatologist in Japan as Clinical Advisor
VANCOUVER, BC / ACCESSWIRE / May 17, 2021 / RepliCel Life Sciences Inc. (OTCPINK:REPCF) (TSXV:RP) (FRA:P6P2) ( RepliCel or the Company ), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to announce that Professor Akimichi Morita, one of Japan s leading dermatology research clinicians, has agreed to be RepliCel s clinical advisor for the development and commercialization of its skin rejuvenation product (RCS-01) in Japan.
The Company, working with industry leaders, CJ Partners, and clinical research organization, Accerise, is currently preparing to support the next-phase clinical research study of its skin rejuvenation cell therapy, RCS-01, in Japan under the Act for Safety of Regenerative Medicine (ASRM) that, upon successfully meeting its endpoints, could lead to a commercial launch of the product in Japan.
RepliCel Announces Appointment of Leading Dermatologist in Japan as Clinical Advisor biospace.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospace.com Daily Mail and Mail on Sunday newspapers.